Curient Issues 21.8 Billion Won Worth of BW and CB… Accelerating Next-Generation ADC Development

▤ Summary

Curient secured 21.8 billion won through a private placement of bond warrants and convertible bonds. The company plans to use the capital to speed up development of next-generation antibody-drug conjugates and expand its ADC pipeline. Curient highlighted its co-development work with Synaffix and its QP101 program, which recently drew attention at a scientific conference. The company said the financing should support ongoing research, non-clinical work, and future clinical progress without creating excessive dilution pressure.

$ Funding

▦ Linked Companies